Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) plus /- docetaxel (D) in CHAARTED (ECOG-ACRIN E3805).

被引：0
|
作者：
McGregor, Bradley Alexander
Wang, Xin Victoria
Hamnvik, Ole-Petter R.
Cheung, Yee Ming
Wei, Xiao X.
Ravi, Praful
Fichorova, Raina N.
Sweeney, Christopher
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.145
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Association of serum steroid levels with survival in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel on ECOG-ACRIN E3805.
    Mostaghel, Elahe A.
    Wang, Xin Victoria
    Marck, Brett
    Matsumoto, Alvin M.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [2] Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805
    Morgans, Alicia K.
    Chen, Yu-Hui
    Jarrard, David F.
    Carducci, Michael
    Liu, Glenn
    Eisenberger, Mario
    Plimack, Elizabeth R.
    Bryce, Alan
    Garcia, Jorge A.
    Dreicer, Robert
    Vogelzang, Nicholas J.
    Picus, Joel
    Shevrin, Daniel
    Hussain, Maha
    DiPaola, Robert S.
    Cella, David
    Sweeney, Christopher J.
    PROSTATE, 2022, 82 (12): : 1176 - 1185
  • [3] Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.
    Tripathi, Abhishek
    Chen, Yu-Hui
    Jarrard, David Frazier
    Hahn, Noah M.
    Garcia, Jorge A.
    Dreicer, Robert
    Liu, Glenn
    Hussain, Maha H. A.
    Shevrin, Daniel H.
    Cooney, Matthew M.
    Eisenberger, Mario A.
    Kohli, Manish
    Plimack, Elizabeth R.
    Vogelzang, Nicholas J.
    Picus, Joel
    Carducci, Michael Anthony
    DiPaola, Robert S.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Impact of baseline serum IL-8 on metastatic hormone-sensitive (mHSPC) prostate cancer outcomes in the phase III CHAARTED trial (E3805)
    Harshman, Lauren Christine
    Wang, Xin Victoria
    Yamamoto, Hidemi S.
    Hamid, Anis
    Drake, Charles G.
    Carducci, Michael Anthony
    DiPaola, Robert S.
    Fichorova, Raina N.
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [5] Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).
    Barata, Pedro C.
    Emamekhoo, Hamid
    Mendiratta, Prateek
    Gopalakrishnan, Dharmesh
    Koshkin, Vadim S.
    Tyler, Allison Janine
    Ornstein, Moshe Chaim
    Grivas, Petros
    Gilligan, Timothy D.
    Rini, Brian I.
    Kyriakopoulos, Christos
    Garcia, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [6] Prognostic validation of a digital pathology-based multi-modal artificial intelligence (MMAI) biomarker in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the CHAARTED trial (ECOG-ACRIN EA3805)
    Markowski, Mark Christopher
    Ren, Yi
    Croucher, Danielle
    Royce, Trevor Joseph
    Yamashita, Rikiya
    Tierney, Meghan
    Huang, Huei-Chung
    Todorovic, Tamara
    Chen, Emmalyn
    Carducci, Michael Anthony
    Chen, Yu-Hui
    Liu, Glenn
    Parker, Charles
    Esteva, Andre
    Feng, Felix Y.
    Attard, Gerhardt
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] KEYNOTE-991: PHASE 3 STUDY OF PEMBROLIZUMAB PLUS ENZALUTAMIDE AND ANDROGEN DEPRIVATION THERAPY (ADT) FOR PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
    Gratzke, Christian
    Gratzke, Christian
    Gratzke, Christian
    Niu, Cuizhen
    Poehlein, Christian
    Burgents, Joseph
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A211 - A211
  • [8] Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC).
    Gill, David Michael
    Stenehjem, David D.
    Cheng, Heather H.
    Kessler, Elizabeth Riley
    Hahn, Andrew W.
    Gupta, Sumati
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [9] Comparative efficacy and cost-effectiveness of maximum androgen blockade (MAB), docetaxel with androgen deprivation therapy (ADT), and ADT alone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in China
    Jiang, W.
    Qu, S.
    Liu, Y.
    Yao, X.
    Liu, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 276 - 276
  • [10] Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Ito, Tetsuro
    Grant, Laura
    Duckham, Bryony R.
    Ribbands, Amanda J.
    Gater, Adam
    ADVANCES IN THERAPY, 2018, 35 (12) : 2186 - 2200
12345